Scroll to the Bottom of this Information to Begin this Course

This activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

Funding for this Independent Medical Education Grant is being provided from Pfizer Inc. and Myovant Sciences Ltd.

Credit Available

• Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the educational needs of medical oncologists, nurse practitioners, and other healthcare professionals who care for patients with prostate cancer.

Program Overview

Join Drs. Robert Dreicer and Michael Cookson as they review the principles of androgen deprivation therapy and discuss the latest clinical data for recently approved ADT agents and studies of ADT-based combination regimens in the treatment of men with metastatic hormone sensitive prostate cancer (mHSPC). The evolving guideline-directed evidence-based approaches for therapeutic intensification in the treatment of mHSPC are also discussed. Listen to the faculty discuss case studies to gain practical insights into choosing optimal therapies that incorporate ADT for individual patients and balance patient preferences with therapeutic goals.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Explain the differences between luteinizing hormone-releasing hormone agonists and gonadotropin-releasing hormone antagonists in terms of mechanism of action and outcomes
• Select optimal therapy to avoid/reduce cardiovascular risk in patients with advanced prostate cancer
• Compare and contrast the latest evidence regarding options for patients with advanced prostate cancer
• Develop treatment strategies incorporating patient-specific factors, including risk factors, concerns, preferences, and adherence information regarding oral vs injectable oncologic therapy

Faculty

Physician Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in accredited education activities are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Robert Dreicer, MD, MS, MACP

• Consultant: Astellas, AstraZeneca, AVEO, Bayer, Eisai, EMD Serono, Exelixis, Gilead, Hinova, Infinity, Janssen, Merck, Myovant, Pfizer, Propella, Seattle Genetics, Tavanta, Veru

Michael S. Cookson, MD, MMHC

• Advisory board : Merck, Myovant, Pfizer

Additional content planners
The following have no significant relationship to disclose:
Kam Newman, MD (peer reviewer)
Krithika Subramanian, PhD (medical writer)

Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Instructions for Participation and Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved applications.

Disclaimer

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Contact Information

For help or questions about this activity please contact Continuing Education:
ce@annenberg.net